Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Asia symbols : AMGN save search
CANbridge Pharmaceuticals Appoints Jason West Vice President, Head of Gene Therapy Research
Published: 2023-05-05 (Crawled : 09:00) - biospace.com/
CRSP | News M | $58.17 4.51% 500K
|
Health Technology
|
| O: 1.88%
H: 6.97%
C: 3.09%
BIIB | $194.93 0.42% 210K
|
Health Technology
|
| O: 0.08%
H: 1.89%
C: 1.35%
AMGN | News | $273.19 0.47% 360K
|
Health Technology
|
| O: 0.33%
H: 1.88%
C: 1.66%
west pharmaceuticals research therapy
Entera Bio to Participate in the SVB Securities Global Biopharma Conference
Published: 2023-02-13 (Crawled : 15:00) - biospace.com/
ENTX | $2.03 -0.98% 20K
|
Health Technology
|
| O: -2.2%
H: 4.49%
C: 1.11%
AMGN | News | $273.19 0.47% 360K
|
Health Technology
|
| O: 0.29%
H: 0.26%
C: 0.19%
biopharma global conference
Entera Bio Hosting Key Opinion Leader Webinar on the Treatment Landscape for Osteoporosis and EB613’s Potential Impact on Wednesday, September 28th @ 10am ET
Published: 2022-09-21 (Crawled : 13:00) - biospace.com/
ENTX | $2.03 -0.98% 20K
|
Health Technology
|
| O: 0.0%
H: 7.73%
C: 6.61%
AMGN | News | $273.19 0.47% 360K
|
Health Technology
|
| O: 0.62%
H: 0.65%
C: -2.04%
eb613 treatment impact potential osteoporosis
Entera Bio to Report First Quarter 2022 Financial Results on May 12
Published: 2022-04-28 (Crawled : 15:00) - biospace.com/
ENTX | $2.03 -0.98% 20K
|
Health Technology
|
| O: -1.73%
H: 2.74%
C: 0.78%
AMGN | News | $273.19 0.47% 360K
|
Health Technology
|
| O: -5.25%
H: 3.05%
C: 1.02%
report results
Entera Bio Announces Successful EB613 End-of-Phase 2 Meeting with FDA
Published: 2022-01-04 (Crawled : 23:00) - biospace.com/
ENTX | $2.03 -0.98% 20K
|
Health Technology
|
| O: 8.57%
H: 0.0%
C: -10.17%
AMGN | News | $273.19 0.47% 360K
|
Health Technology
|
| O: -0.41%
H: 0.0%
C: 0.0%
eb613 fda phase 2 613
Kyowa Kirin to Present Atopic Dermatitis Clinical Data from KHK4083/AMG 451 Phase 2 Study at The European Academy of Dermatology and Venereology 30th Congress
Published: 2021-09-13 (Crawled : 14:00) - biospace.com/
AMGN | News | $273.19 0.47% 360K
|
Health Technology
|
| O: 1.55%
H: 0.92%
C: -0.16%
phase 2 europe dermatitis atopic dermatitis
Asieris and BeiGene Enter into Clinical Collaboration to Evaluate Combinations of APL-1202 and Tislelizumab
Published: 2021-05-06 (Crawled : 14:15) - biospace.com/
BGNE | $140.43 7.25% 88K
|
Health Technology
|
| O: 0.14%
H: 3.67%
C: 2.67%
AMGN | News | $273.19 0.47% 360K
|
Health Technology
|
| O: -0.03%
H: 0.88%
C: 0.81%
collaboration
Entera Bio to Report Financial Results for the Year Ended December 31, 2020 on March 18, 2021
Published: 2021-03-11 (Crawled : 22:04) - biospace.com/
ENTX | $2.03 -0.98% 20K
|
Health Technology
|
| O: 190.63%
H: 69.25%
C: -13.12%
AMGN | News | $273.19 0.47% 360K
|
Health Technology
|
| O: 0.3%
H: 1.43%
C: 0.22%
financial results results
Gainers vs Losers
| 87% | 13% |
Top 10 Gainers
MTTR | News M | $4.595 164.08% 13M
|
AGBA | $2.355 88.4% 34M
|
Finance
CZOO | $9.32 86.77% 18M
|
EDBL | News | $6.75 79.52% 1.5M
|
MTC | $2.28 46.15% 2.6M
|
Technology Services
OPRT | News | $3.14 39.56% 7.6M
|
Finance
VNRX | $0.8 33.33% 2.9M
|
Health Technology
MLEC | $1.865 33.21% 2.4M
|
n/a
PALI | $6.37 29.21% 21M
|
Manufacturing
LOCL | $3.33 27.59% 43K
|
Your saved searches
Save your searches and get alerts when important news are released.